Evidence map›Paper›PMID 38089921›Full record

ReviewInterdisciplinary medicine2023

Progress and prospect of nanotechnology for cardiac fibrosis treatment.

Samantha L Gaytan, Elfa Beaven, Shrikanth S Gadad, Md Nurunnabi

Open access · diamondAbstract readReview
In one paragraph

Review in Interdisciplinary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Samantha L GaytanDepartment of Pharmaceutical Sciences School of Pharmacy The University of Texas El Paso El Paso Texas USA.
Elfa BeavenDepartment of Pharmaceutical Sciences School of Pharmacy The University of Texas El Paso El Paso Texas USA.
Shrikanth S GadadCenter of Emphasis in Cancer Department of Molecular and Translational Medicine Paul L. Foster School of Medicine Texas Tech University Health Sciences Center El Paso El Paso Texas USA.
Md NurunnabiDepartment of Pharmaceutical Sciences School of Pharmacy The University of Texas El Paso El Paso Texas USA.ORCID https://orcid.org/0000-0003-4457-3401
The University of Texas at El Paso · USTexas Tech University · US

Funding

A Novel Hyper-Immunogenic Low Virulent BCG vaccine against TuberculosisR01AI175837 · NIAID · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI SUBRAMANIAN DHANDAYUTHAPANI · 2023 to 2026
$2.0M
NIAID NIH HHS R01 AI175837
6 · The paper itself

Abstract

Cardiac fibrosis is the excessive accumulation of extracellular matrix components in the heart, leading to reduced cardiac functionality and heart failure. This review provides an overview of the therapeutic applications of nanotechnology for the treatment of cardiac fibrosis. We first delve into the fundamental pathophysiology of cardiac fibrosis, highlighting the key molecular players, including Matrix Metalloproteinases, Transforming Growth Factor-beta, and several growth factors, cytokines, and signaling molecules. Each target presents a unique opportunity to develop targeted nano-therapies. We then focus on recent advancements in nanotechnology and how nanoparticles can be engineered to deliver drugs or therapeutic genes. These advanced delivery approaches have shown significant potential to inhibit fibrosis-promoting factors, thereby mitigating the fibrotic response and potentially reversing disease progression. In addition, we discuss the challenges associated with developing and translating nanotechnology-based drug delivery systems, including ensuring biocompatibility, safety, and regulatory compliance. This review highlights how nanotechnology can bridge the gap between lab research and clinical practice for treating cardiac fibrosis.

Indexed as

cardiac fibrosisdrug delivery systemsnanomedicinenanotechnologypharmacological interventions

Identifiers

PMID38089921
PMCPMC10712437
OpenAlexW4386439940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.